G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St climbs after August inflation report, oil price slide
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for 8% weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
G1 Therapeutics, Inc. (GTHX) Tops Q2 EPS by 36c, Reiterates Guidance
August 2, 2023 6:34 AM EDTG1 Therapeutics, Inc. (NASDAQ: GTHX) reported Q2 EPS of $0.14, $0.36 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $42.4 million versus the consensus estimate of $28.95 million.
G1 today reiterated its full year 2023 net revenue guidance. The Company expects to generate... More
